This has been demonstrated experimentally using gene therapy approaches, where increasing cellular frataxin levels through viral delivery of a FXN transgene led to robust correction of cellular parameters in models of FA,39, 40 in both cell culture and myocardial tissue. Here, FXN is linked to Friedreich ataxia.